The safety of enalapril upward titration in chronic heart failure

A. Makoto, I. Shiro, Keiichi Fukuda, O. Satoshi

Research output: Contribution to journalArticle

Abstract

We investigated the safety of enalapril, an ACE inhibitor, upward titration in chronic heart failure with ejection fraction (EF) ≤0.40. Eleven patients who received digitalis, diuretics and enalapril (5 mg over 4 weeks) were enrolled and divided to two groups. Four patients were kept or enalapril 5 mg (Maintenance group) and seven patients were titrated upward to 10 mg (Titration group). These medications were continued for 3 months. There were no significant changes with regard to average values of 24h blood pressure, average counts of ventricular premature beats, left ventricular EF, left ventricular end-diastolic dimension (LVDd) and LVDs in either of the two groups. Although neurohormonal levels in the Maintenance group did not change significantly, brain natriuretic peptide (BNP) in the Titration group decreased significantly. There were no dropout patients in the Titration group, because the upward titration of enalapril did not decrease blood pressure and did not cause any adverse effects. Taking the results of the ATLAS study into account, we strongly support the suggestion that enalapril should be titrated upward in chronic heart failure with SBP≥90 mmHg.

Original languageEnglish
Pages (from-to)1061-1066
Number of pages6
JournalRespiration and Circulation
Volume48
Issue number10
Publication statusPublished - 2000
Externally publishedYes

Fingerprint

Enalapril
Heart Failure
Safety
Maintenance
Blood Pressure
Patient Dropouts
Ventricular Premature Complexes
Digitalis
Brain Natriuretic Peptide
Angiotensin-Converting Enzyme Inhibitors
Diuretics
Stroke Volume

Keywords

  • Chronic heart failure
  • Enalapril
  • Titration

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Pulmonary and Respiratory Medicine

Cite this

The safety of enalapril upward titration in chronic heart failure. / Makoto, A.; Shiro, I.; Fukuda, Keiichi; Satoshi, O.

In: Respiration and Circulation, Vol. 48, No. 10, 2000, p. 1061-1066.

Research output: Contribution to journalArticle

Makoto, A, Shiro, I, Fukuda, K & Satoshi, O 2000, 'The safety of enalapril upward titration in chronic heart failure', Respiration and Circulation, vol. 48, no. 10, pp. 1061-1066.
Makoto, A. ; Shiro, I. ; Fukuda, Keiichi ; Satoshi, O. / The safety of enalapril upward titration in chronic heart failure. In: Respiration and Circulation. 2000 ; Vol. 48, No. 10. pp. 1061-1066.
@article{a037db0ad12e4027801b78c0930d6536,
title = "The safety of enalapril upward titration in chronic heart failure",
abstract = "We investigated the safety of enalapril, an ACE inhibitor, upward titration in chronic heart failure with ejection fraction (EF) ≤0.40. Eleven patients who received digitalis, diuretics and enalapril (5 mg over 4 weeks) were enrolled and divided to two groups. Four patients were kept or enalapril 5 mg (Maintenance group) and seven patients were titrated upward to 10 mg (Titration group). These medications were continued for 3 months. There were no significant changes with regard to average values of 24h blood pressure, average counts of ventricular premature beats, left ventricular EF, left ventricular end-diastolic dimension (LVDd) and LVDs in either of the two groups. Although neurohormonal levels in the Maintenance group did not change significantly, brain natriuretic peptide (BNP) in the Titration group decreased significantly. There were no dropout patients in the Titration group, because the upward titration of enalapril did not decrease blood pressure and did not cause any adverse effects. Taking the results of the ATLAS study into account, we strongly support the suggestion that enalapril should be titrated upward in chronic heart failure with SBP≥90 mmHg.",
keywords = "Chronic heart failure, Enalapril, Titration",
author = "A. Makoto and I. Shiro and Keiichi Fukuda and O. Satoshi",
year = "2000",
language = "English",
volume = "48",
pages = "1061--1066",
journal = "Respiration and Circulation",
issn = "0452-3458",
publisher = "Igaku-Shoin Ltd",
number = "10",

}

TY - JOUR

T1 - The safety of enalapril upward titration in chronic heart failure

AU - Makoto, A.

AU - Shiro, I.

AU - Fukuda, Keiichi

AU - Satoshi, O.

PY - 2000

Y1 - 2000

N2 - We investigated the safety of enalapril, an ACE inhibitor, upward titration in chronic heart failure with ejection fraction (EF) ≤0.40. Eleven patients who received digitalis, diuretics and enalapril (5 mg over 4 weeks) were enrolled and divided to two groups. Four patients were kept or enalapril 5 mg (Maintenance group) and seven patients were titrated upward to 10 mg (Titration group). These medications were continued for 3 months. There were no significant changes with regard to average values of 24h blood pressure, average counts of ventricular premature beats, left ventricular EF, left ventricular end-diastolic dimension (LVDd) and LVDs in either of the two groups. Although neurohormonal levels in the Maintenance group did not change significantly, brain natriuretic peptide (BNP) in the Titration group decreased significantly. There were no dropout patients in the Titration group, because the upward titration of enalapril did not decrease blood pressure and did not cause any adverse effects. Taking the results of the ATLAS study into account, we strongly support the suggestion that enalapril should be titrated upward in chronic heart failure with SBP≥90 mmHg.

AB - We investigated the safety of enalapril, an ACE inhibitor, upward titration in chronic heart failure with ejection fraction (EF) ≤0.40. Eleven patients who received digitalis, diuretics and enalapril (5 mg over 4 weeks) were enrolled and divided to two groups. Four patients were kept or enalapril 5 mg (Maintenance group) and seven patients were titrated upward to 10 mg (Titration group). These medications were continued for 3 months. There were no significant changes with regard to average values of 24h blood pressure, average counts of ventricular premature beats, left ventricular EF, left ventricular end-diastolic dimension (LVDd) and LVDs in either of the two groups. Although neurohormonal levels in the Maintenance group did not change significantly, brain natriuretic peptide (BNP) in the Titration group decreased significantly. There were no dropout patients in the Titration group, because the upward titration of enalapril did not decrease blood pressure and did not cause any adverse effects. Taking the results of the ATLAS study into account, we strongly support the suggestion that enalapril should be titrated upward in chronic heart failure with SBP≥90 mmHg.

KW - Chronic heart failure

KW - Enalapril

KW - Titration

UR - http://www.scopus.com/inward/record.url?scp=0033776201&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033776201&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:0033776201

VL - 48

SP - 1061

EP - 1066

JO - Respiration and Circulation

JF - Respiration and Circulation

SN - 0452-3458

IS - 10

ER -